CLDN8 and breast carcinoma: Given that HER2(+) breast cancers often receive agents such as trastuzumab or kinase inhibitors, we analyzed CLDN8’s association with treatment response in HER2+ patient subgroups and validated the findings in HER2-driven cell models.